Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02537548 · ClinicalTrials.gov registry record · NA
Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma
A NA study of Lymphadenopathy and Stage I Testicular Seminoma, sponsored by University of Southern California.
- Active
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 14
- Study locations
NCT02537548 is a NA study of Lymphadenopathy and Stage I Testicular Seminoma that is active but no longer recruiting, run by University of Southern California. The registered enrollment target is 55 participants, below the 70-participant average among 5 other Lymphadenopathy trials with a reported enrollment target (21% lower). The trial reports 14 study locations across 11 states.
The verdict
NCT02537548, a NA study of Lymphadenopathy and Stage I Testicular Seminoma, is active but no longer recruiting, sponsored by University of Southern California.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 14
- Study locations
Study Summary
This phase II trial studies how well retroperitoneal lymph node dissection (RPLND) works in treating patients with stage I-IIa testicular seminoma. The retroperitoneum is the space in the body behind the intestines that is typically the first place that seminoma spreads. RPLND is a surgery that removes lymph nodes in this area to treat testicular seminoma and may experience fewer long-term toxicities, such as a second cancer, cardiovascular disease, metabolic syndrome (pre-diabetes), or lung disease.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Retroperitoneal Lymph Node Dissection
Study Locations (14)
California
- Loma Linda University Medical Center - Loma Linda
- USC / Norris Comprehensive Cancer Center - Los Angeles
- University of California, San Francisco - San Francisco
- Stanford University Hospitals & Clinics - Stanford
Colorado
- University of Colorado Hospital - Aurora - Aurora
Georgia
- Emory University - Atlanta
Illinois
- University of Chicago Medical Center - Chicago
Indiana
- Indiana University - Indianapolis
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Minnesota
- Mayo Clinic - Rochester
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2015-08-28 |
| Est. Completion | 2027-08-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02537548
The ClinicalTrials.gov registry entry for NCT02537548 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 70-participant average among 5 other Lymphadenopathy trials with a reported enrollment target (21% lower). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lymphadenopathy appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02537548 reports 14 study locations spanning 11 distinct geographic areas - top geographies include California, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT02537548 about?
NCT02537548 is a clinical study titled "Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma". This phase II trial studies how well retroperitoneal lymph node dissection (RPLND) works in treating patients with stage I-IIa testicular seminoma. The retroperitoneum is the space in the body behind the intestines that is typically the first place that seminoma spreads. RPLND is a surgery that remo...
What is the current status of trial NCT02537548?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 55 participants. The study started on 2015-08-28. Estimated completion is 2027-08-28.
What conditions does trial NCT02537548 study?
This clinical trial studies the following conditions: Lymphadenopathy, Stage I Testicular Seminoma, Stage II Testicular Seminoma.
What interventions are being tested in trial NCT02537548?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Retroperitoneal Lymph Node Dissection (PROCEDURE).
Who is sponsoring clinical trial NCT02537548?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02537548 being conducted?
This trial has 14 study locations across California, Colorado, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphadenopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
COMPLETED · NA
-
The Analysis of the EBUS Scope as a Hybrid Bronchoscope
COMPLETED · NA
-
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
ACTIVE NOT RECRUITING · Phase 2
-
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
COMPLETED
-
Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.